Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Employees

674

Sector

Pharmaceuticals

Calendar

12-08 - Bank of America Securities CNS Therapeutics Virtual Conference

More about the company

Quotes

Date	Price	Change	Volume
25-12-05	45.68 $	+1.29%	458,559
25-12-04	45.10 $	+0.76%	493,658
25-12-03	44.76 $	+1.45%	527,464
25-12-02	44.12 $	-1.30%	624,380
25-12-01	44.70 $	-1.95%	565,144

Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.68USD

Average target price

60.50USD

Spread / Average Target

+32.44%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-05 EST			5-day change	1st Jan Change
45.68 ^USD	+1.29%		+0.20%	+26.33%

11-08	Supernus Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 04, 2025
11-04	Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q3 Revenue $192.1M, vs. FactSet Est of $180.2M	MT

Capitalization	2.62B 2.25B 2.11B 1.97B 3.63B 236B 3.95B 24.67B 9.53B 111B 9.83B 9.62B 407B	P/E ratio 2025 *	-59.1x	P/E ratio 2026 *	26x
Enterprise value	2.62B 2.25B 2.11B 1.97B 3.63B 236B 3.95B 24.67B 9.53B 111B 9.83B 9.62B 407B	EV / Sales 2025 *	3.73x	EV / Sales 2026 *	3.02x
Free-Float	94.99%	Yield 2025 *	-	Yield 2026 *	-

11-08	Supernus Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 04, 2025
11-04	Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q3 Revenue $192.1M, vs. FactSet Est of $180.2M	MT
11-04	Supernus Pharma Q3 revenue rises, partly helped by Sage acquisition	RE
11-04	Supernus Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2025	CI
11-04	Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-29	BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target	MT
10-10	Supernus Pharmaceuticals Insider Sold Shares Worth $3,029,336, According to a Recent SEC Filing	MT
10-09	Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade	MT
10-09	Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40	MT
10-02	Supernus Pharmaceuticals Insider Sold Shares Worth $1,931,116, According to a Recent SEC Filing	MT
09-30	Supernus Pharmaceuticals Insider Sold Shares Worth $491,485, According to a Recent SEC Filing	MT
09-24	Supernus Pharmaceuticals Insider Sold Shares Worth $1,393,899, According to a Recent SEC Filing	MT
09-23	Supernus Pharmaceuticals Insider Sold Shares Worth $779,921, According to a Recent SEC Filing	MT

10-29	BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target	MT
10-09	Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade	MT
10-09	Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40	MT
07-30	Supernus Shares Rise After Upgrade From Cantor Fitzgerald	MT
07-30	Cantor Fitzgerald Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $42 From $36	MT

Supernus Pharmaceuticals, Inc. Stock

Equities

SUPN

US8684591089

Pharmaceuticals

Valuation: Supernus Pharmaceuticals, Inc.

Chart: Supernus Pharmaceuticals, Inc.

Latest news: Supernus Pharmaceuticals, Inc.

Last Transcript: Supernus Pharmaceuticals, Inc.

Analysts' recommendations: Supernus Pharmaceuticals, Inc.

Press Releases: Supernus Pharmaceuticals, Inc.

News in other languages: Supernus Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Supernus Pharmaceuticals, Inc.

ETFs: Supernus Pharmaceuticals, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-03	Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference	GL
11-21	Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference	GL
11-12	Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London	GL
11-04	Supernus: Q3 Earnings Snapshot	AQ
11-04	Supernus Announces Third Quarter 2025 Financial Results	GL

02-19	USA-Les valeurs à suivre à Wall Street (actualisé)
02-19	En direct des marchés : Sanofi vend Opella, Stellantis revient au diesel, Intel à la découpe
02-19	"Les actions US sont trop chères, mais on s'en fout"
21-10-18	Newron erhält fünfte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
21-10-18	Newron erhält fünfte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)

1 day	+1.29%
1 week	+0.20%
Current month	+0.20%
1 month	-3.04%
3 months	-0.70%
6 months	+41.25%
Current year	+26.33%

1 week	44.09	45.88
1 month	44.05	47.48
Current year	29.16	57.65
1 year	29.16	57.65
3 years	21.99	57.65
5 years	20.81	57.65
10 years	9.51	61.25

Manager	Title	Age	Since
Jack Khattar CEO	Chief Executive Officer	63	2005-12-21
Timothy Dec DFI	Director of Finance/CFO	66	2021-08-22
Kevin T. Anderson CMP	Compliance Officer	62	2011-12-31

Director	Title	Age	Since
Jack Khattar BRD	Director/Board Member	63	2005-12-21
Charles Newhall CHM	Chairman	79	2016-08-09
Frederick Hudson BRD	Director/Board Member	79	2010-11-15

Name	Weight	AuM	Varia. Jan 1.	Investor
HARTFORD MULTIFACTOR SMALL CAP ETF - USD	0.94%	29 M€	+7.52%	-
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD	0.38%	22 M€	+1.27%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SUPERNUS PHARMACEUTICALS, INC.	+1.29%	+0.20%	+23.49%	+28.28%	2.62B
MERCK KGAA	+1.21%	+4.18%	-13.65%	-31.61%	61.02B
KYOWA KIRIN CO., LTD.	-1.01%	-3.33%	+4.07%	-19.78%	8.57B
HALOZYME THERAPEUTICS, INC.	+0.60%	-11.30%	+31.77%	+13.21%	7.45B
SK BIOPHARMACEUTICALS CO., LTD.	-1.69%	-4.15%	+28.72%	+84.57%	7.12B
YUHAN CORPORATION	-0.93%	-3.85%	+0.34%	+122.97%	5.94B
INDIVIOR PLC	+1.50%	+4.52%	+212.18%	+67.16%	4.38B
BETTA PHARMACEUTICALS CO., LTD.	+0.61%	-3.01%	-13.95%	-4.68%	2.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.67%	+1.50%	+21.67%	+62.21%	2.54B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+0.19%	+0.39%	-14.34%	+5.62%	1.96B
Average	+0.11%	-1.49%	+28.03%	+32.80%	10.44B
Weighted average by Cap.	+0.60%	+1.08%	+5.98%	-1.36%

	2025 *	2026 *
Net sales	703M 604M 566M 528M 974M 63.25B 1.06B 6.62B 2.56B 29.87B 2.64B 2.58B 109B	867M 745M 698M 651M 1.2B 78.03B 1.31B 8.17B 3.15B 36.85B 3.25B 3.18B 135B
Net income	-43.55M -37.44M -35.07M -32.69M -60.38M -3.92B -65.67M -410M -158M -1.85B -163M -160M -6.77B	99.71M 85.71M 80.29M 74.84M 138M 8.97B 150M 939M 363M 4.24B 374M 366M 15.5B
Net Debt	-	-